Supplementary Materials

This PDF file includes:

  • Materials and Methods
  • Fig. S1. PRISMA 2009 flow diagram.
  • Fig. S2. Adjusted odds ratios for amodiaquine, TKM-130803, Prevail II–ZMapp, and IFN-β1a study treatment arms for patients with a cycle threshold of ≥20 relative to each control group.
  • Fig. S3. Adjusted odds ratios for Favi-JIKI, convalescent plasma, Favi-Bai, and convalescent whole-blood study treatment arms for patients with a cycle threshold of ≥20 relative to each control group.
  • Fig. S4. Adjusted odds ratios for treatment relative to each of six control groups for patients of the TKM-130803 study, from the per-protocol and intent-to-treat samples.
  • Table S1. Weighted least squares regression for models in Fig. 1, evaluating association of midpoint of study enrollment dates and mortality rate/cycle threshold.
  • Table S2. Model estimates from logistic regression models for Fig. 2D.
  • Table S3. Model estimates from logistic regression models for Fig. 3 (A to D).
  • Table S4. Model estimates from logistic regression models for Fig. 4 (A to D).
  • Table S5. PRISMA 2009 checklist.

[Download PDF]